in vivo News and Research

RSS

Development of a potential pan-variant aerosol to manage COVID-19

Researchers hypothesized that if APN01 could be directly introduced into the airways of an infected person, it could locally neutralize SARS-CoV-2.

19 Sep 2021

A 100% French nasal vaccine against SARS-CoV-2 to move into the clinical phase in 2022

In contrast to intramuscular vaccines, only nasal vaccines are able to block the virus in the nose by inducing local immunity in the nasal mucosa, i.e. the portal of entry and multiplication of the virus.

18 Sep 2021

Organs-on-chips for personalized medicine and to assess drug efficacy

Organs-on-chips could be used to assess drug efficacy and support personalized medicine, write Adrian Roth and colleagues in a Perspective.

17 Sep 2021

Antiviral compound RG10 acts via intracellular SARS-CoV-2-ER dynamics

A new study describes a small molecule referred to as RG10 that may have potent antiviral activity against SARS-CoV-2 in human cells.

16 Sep 2021

Neutralizing monoclonal antibodies provide Fc receptor-independent SARS-CoV-2 protection in Hamsters

A study published in the journal mBio analyzes the capacity of the neutralizing MAb 2B04 to protect different antibody titers.

16 Sep 2021

Novel cell reprogramming offers a promising therapeutic strategy to slow down glioblastomas

Gliomas are the most common primary brain tumors in adults. Among them, high-grade glioblastomas (GBMs) are particularly known to be notoriously aggressive and invasive, which makes it challenging to treat them. The disease rapidly progresses to an advanced stage in a short span of time, and the survival of such patients is often dismal.

16 Sep 2021

Evolved SARS-CoV-2 viruses gain higher infectivity and cause more rapid infection spread

Viruses accumulate mutations as they replicate in infected cells. Repeated replication can lead to viral strains that show attenuated virulence. Such strains may act as vaccines if the attenuated virus can produce immunity without serious disease.

16 Sep 2021

Phase I trial investigates using antiparasitic nitazoxanide for treatment of COVID-19

In a recent study, researchers investigate the possibility of using the thiazolide antiparasitic nitazoxanide for the treatment of COVID-19.

15 Sep 2021

A sweet pill to swallow: oral nucleoside analog of Remdesivir improved SARS-CoV-2 pathogenesis in mice

A new study focused on in vitro antiviral activity in various cell models and in vivo therapeutic efficacy of oral GS-621763 in a mouse model of SARS-CoV-2 pathogenesis.

15 Sep 2021

A protein found to be effective at reversing aging in skeletal muscle cells

A University at Buffalo-led research team has shown that a protein named for the mythical land of youth in Irish folklore is effective at reversing aging in skeletal muscle cells.

15 Sep 2021

Scientists develop a novel and potent SARS-CoV-2 RBD-homodimer vaccine

A recent report published in the journal Cell Discovery has described the immunogenicity and protective efficacy of a novel coronavirus disease 2019 (COVID-19) subunit vaccine candidate. The vaccine induces robust immune responses in rodents and non-human primates and protects the animals against severe disease.

12 Sep 2021

UGA research offers hope for a viable therapeutic to combat COVID-19

As COVID-19 cases continue to skyrocket across the U.S. and the world, few options are available for treating patients infected with the SARS-CoV-2.

11 Sep 2021

Nanoparticles-assisted delivery of antiviral-siRNA for treatment of COVID-19

A review aimed to determine the potential of siRNA as a potential COVID-19 treatment by reviewing the currently available literature.

10 Sep 2021

New gene-delivering workhorse could make gene therapy safer, more effective for muscle diseases

Genetic muscle diseases lead to progressive muscle wasting and often early death, with few treatment options and no cure.

9 Sep 2021

Potential pancoronavirus fusion inhibitors that are effective against SARS-CoV-2 variants

A new study successfully identifies a series of inhibitors that possesses pancoronavirus activity against SARS-CoV, SARS-CoV-2, and MERS-CoV.

7 Sep 2021

Study sheds light on neurologic symptoms caused by SARS-CoV-2 infection

Researchers in Australia and Finland have provided important insights into how infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19) – might affect nervous system circuitries and cause neurologic symptoms.

6 Sep 2021

Researchers develop the smallest CRISPR to date for genome editing

A compact and efficient CRISPR-Cas system, named CasMINI, could be broadly useful for cell-engineering and gene-therapy applications because it is easier to deliver into cells. The findings appear in a study publishing September 3 in the journal Molecular Cell.

4 Sep 2021

Antibody cocktail neutralizes SARS-CoV-2 and has projected protection up to 12 months

A new study reports long-lasting, effective protection against severe disease with the AZD7442 antibody cocktail.

3 Sep 2021

First-in-human trial proves feasibility of Temporally Feathered Radiation Therapy

Researchers from Cleveland Clinic and OhioHealth have published results from a first-in-human trial evaluating feasibility of Temporally Feathered Radiation Therapy (TFRT), which is designed to reduce the toxicity of radiation treatment.

1 Sep 2021

Impact of neoadjuvant concurrent chemoradiation on exosomal markers expression in colorectal cancer

Oncotarget published "The impact of neoadjuvant concurrent chemoradiation on exosomal markers (CD63 and CD9) expression and their prognostic significance in patients with rectal adenocarcinoma" which reported that the impact of neoadjuvant concurrent chemoradiation on exosomal markers expression and their prognostic significance in patients with rectal adenocarcinoma are yet to be explored.

1 Sep 2021

in vivo News and Research

Development of a potential pan-variant aerosol to manage COVID-19

A 100% French nasal vaccine against SARS-CoV-2 to move into the clinical phase in 2022

Organs-on-chips for personalized medicine and to assess drug efficacy

Antiviral compound RG10 acts via intracellular SARS-CoV-2-ER dynamics

Neutralizing monoclonal antibodies provide Fc receptor-independent SARS-CoV-2 protection in Hamsters

Novel cell reprogramming offers a promising therapeutic strategy to slow down glioblastomas

Evolved SARS-CoV-2 viruses gain higher infectivity and cause more rapid infection spread

Phase I trial investigates using antiparasitic nitazoxanide for treatment of COVID-19

A sweet pill to swallow: oral nucleoside analog of Remdesivir improved SARS-CoV-2 pathogenesis in mice

A protein found to be effective at reversing aging in skeletal muscle cells

Scientists develop a novel and potent SARS-CoV-2 RBD-homodimer vaccine

UGA research offers hope for a viable therapeutic to combat COVID-19

Nanoparticles-assisted delivery of antiviral-siRNA for treatment of COVID-19

New gene-delivering workhorse could make gene therapy safer, more effective for muscle diseases

Potential pancoronavirus fusion inhibitors that are effective against SARS-CoV-2 variants

Study sheds light on neurologic symptoms caused by SARS-CoV-2 infection

Researchers develop the smallest CRISPR to date for genome editing

Antibody cocktail neutralizes SARS-CoV-2 and has projected protection up to 12 months

First-in-human trial proves feasibility of Temporally Feathered Radiation Therapy

Impact of neoadjuvant concurrent chemoradiation on exosomal markers expression in colorectal cancer

eBook: Using iPSCs models for human disease research and drug discovery eBook

Lab Matters host Harriet Gould on building a more connected lab community

The Critical Role of Sample Storage in Drug Discovery and Development

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

Latest News